News & Updates
Showing Urology articles
Showing

Cefepime–taniborbactam bests meropenem for complicated UTI
Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.

Is MFS a valid surrogate for OS in prostate cancer?
Metastasis-free survival (MFS) is still a good proxy for overall survival (OS) as endpoint in the current era, wherein patients have more access to docetaxel and other treatments for metastatic castrate-resistant prostate cancer (mCRPC), according to a study.

Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.

Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.

TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.



